Unconfigured Ad

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts
  • NextGenSeq
    Senior Member
    • Apr 2009
    • 482

    A Hammer Thrown at Big Brother?

    Oxford Nanopore Technologies, the company that pioneered a new DNA analysis technique called nanopore sequencing, has remained secretive about the microscopic channel at the heart of its products. But on the heels of a patent infringement lawsuit from sequencing behemoth Illumina, Inc., the company has revealed what will drive its newest devices—a bacterial pore that seems to circumvent Illumina’s challenge.
    ...
    A webcast presentation today for customers of the company will likely put many of those fears to rest. Oxford Nanopore’s Chief Technology Officer Clive Brown announced an upgrade to its devices—a new pore the company has been describing in presentations as R9. Brown revealed that R9 is CsgG, a membrane protein derived from Escherichia coli, but present in many bacterial species.



  • ymc
    Senior Member
    • Mar 2010
    • 496

    #2
    If the accuracy of R9 chemistry plus RNN algorithm is true, then both PacBio and Illumina will be dead.

    However, judging from ONT's past record, this might well be achievable but the timeline is more likely to be one or two years in the future. As a result, this lawsuit can still be a distraction for ONT for the time being IMHO.
    Attached Files

    Comment

    • luc
      Senior Member
      • Dec 2010
      • 469

      #3
      Originally posted by ymc View Post
      If the accuracy of R9 chemistry plus RNN algorithm is true, then both PacBio and Illumina will be dead.
      I believe the track record of ONP/Clive Brown announcements is pretty abysmal.

      Comment

      • ymc
        Senior Member
        • Mar 2010
        • 496

        #4
        Originally posted by luc View Post
        I believe the track record of ONP/Clive Brown announcements is pretty abysmal.
        Yeah, so far they only delivered Minion and it was at least two years late.

        Comment

        • AllSeq
          Registered Vendor
          • Oct 2013
          • 138

          #5
          Originally posted by ymc View Post
          If the accuracy of R9 chemistry plus RNN algorithm is true, then both PacBio and Illumina will be dead.
          Matching the error rate of PacBio would indeed be pretty impressive, but that alone is insufficient to kill off PacBio or Illumina. The question is does the ONT error profile match that of PacBio? In other words, is it stochastic and relatively free of GC bias so that at sufficient coverage the consensus error rate drops to very low levels (like PacBio). Or does it suffer from systematic errors that create a ceiling to the consensus read quality? Have these questions been definitely answered yet?
          AllSeq - The Sequencing Marketplace
          [email protected]
          www.AllSeq.com

          Comment

          Latest Articles

          Collapse

          • SEQadmin2
            Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
            by SEQadmin2



            Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
            ...
            07-09-2026, 11:10 AM
          • SEQadmin2
            Cancer Drug Resistance: The Lingering Barrier to Rising Survival
            by SEQadmin2



            Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.

            There is no single reason why many patients don’t respond to treatment as expected. Cancer is...
            07-08-2026, 05:17 AM
          • GATTACAT
            Reply to Nine Things a Sample Prep Scientist Thinks About Before Sequencing
            by GATTACAT
            Love this - good data definitely starts from good input, and poor input can only give relatively poor data. I particularly like the mention of Nanodrop/absorbance based methods for quantification. It's such a toss up if you'll get an accurate reading or what amounts to a randomly generated number, and a lot of library/sequencing related issues can be traced back to poor quant.
            07-01-2026, 11:43 AM

          ad_right_rmr

          Collapse

          News

          Collapse

          Topics Statistics Last Post
          Started by SEQadmin2, 07-13-2026, 10:26 AM
          0 responses
          24 views
          0 reactions
          Last Post SEQadmin2  
          Started by SEQadmin2, 07-09-2026, 10:04 AM
          0 responses
          33 views
          0 reactions
          Last Post SEQadmin2  
          Started by SEQadmin2, 07-08-2026, 10:08 AM
          0 responses
          21 views
          0 reactions
          Last Post SEQadmin2  
          Started by SEQadmin2, 07-07-2026, 11:05 AM
          0 responses
          34 views
          0 reactions
          Last Post SEQadmin2  
          Working...